1987PubMedRequires access

[Adoptive immunotherapy in patients with malignant glioma].

S Yoshida, N Takai, Toshihiro Saito, Reina Tanaka

Open publisher page 2 citations

Abstract

We report preliminary results of adoptive immunotherapy in 12 patients with malignant glioma. The patients received both 1.8 to 20 X 10(8) autologous lymphokine activated killer (LAK) cells, and 8 to 16 X 10(4) units of interleukin-2. Objective regression of the tumor was observed in 8 patients. In 4 cases, the size of the tumor was remarkably reduced. No severe side effects were observed. Furthermore, LAK cells and their precursor cells were serologically studied.

About this research paper

What this paper is about

We report preliminary results of adoptive immunotherapy in 12 patients with malignant glioma. The patients received both 1.8 to 20 X 10(8) autologous lymphokine activated killer (LAK) cells, and 8 to 16 X 10(4) units of interleukin-2. Objective regression of the tumor was observed in 8 patients. In 4 cases, the size of the tumor was remarkably reduced. No severe side effects were observed. Furthermore, LAK cells and their precursor cells were serologically studied.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We report preliminary results of adoptive immunotherapy in 12 patients with malignant glioma. The patients received both 1.8 to 20 X 10(8) autologous lymphokine activated killer (LAK) cells, and 8 to 16 X 10(4) units of interleukin-2. Objective regression of the tumor was observed in 8 patients. In 4 cases, the size of the tumor was remarkably reduced. No severe side effects were observed. Furthermore, LAK cells and their precursor cells were serologically studied.

Key concepts: Adoptive immunotherapy, Lymphokine-activated killer cell, Glioma, Immunotherapy, Lymphokine, Adoptive cell transfer, Medicine, Interleukin 2

Related papers

Back to paper searchBrowse research topicsOriginal source
[Adoptive immunotherapy in patients with malignant glioma]. — Research Paper | ScholarLens